● WEEKEND | NEXT OPEN: 2026-09-14 09:30 ET | 07:19 ET | PRICES DELAYED 15 MIN | NYSE · NASDAQ · TSX

ABCL is the most slept-on biotech binary event of 2026 and you're all too busy buying 0DTE SPY puts to notice

BULLISH by u/supy99 | Jun 01, 2026 | 1↑ 0 comments | 38 views | VIEW ON REDDIT
$ABCL
$ABCL ABCELLERA BIOLOGICS INC. HEALTHCARE EQUITY SIMULATION
$7.12
+0.46 (+6.91%)
LAST PRICE · 15 MIN DELAY
DAY CHG +6.91%
5D CHG +28.75%
30D CHG +47.72%
AI SUMMARY — ABCL is a Canadian biotech with a Phase 2 readout expected Q3 2026 for ABCL-635 (hot flash treatment) in a ~$6B market, backed by $655M liquidity and 4-5 years of runway without dilution risk. Binary event catalyst with management calling it their most important readout ever, but carries 40-50% downside risk if Phase 2 misses.
TICKERABCL USERu/supy99
RATING BULLISH ENTRY $6.17
POSITION 1620 sh SYN BOOK VAL $9995.40
CURRENT $7.12 P&L % +15.40%
CURR VAL $11534.24 P&L $ +1538.84

Alright degenerates, put down the weekly options for 5 minutes and hear me out.

AbCellera Biologics (ABCL) — Canadian biotech, antibody discovery platform, and the company about to drop a Phase 2 readout that management literally called "by far the most important data readout in 2026." When management says that, you listen.

THE PLAY:

ABCL-635 is a treatment for postmenopausal vasomotor symptoms (hot flashes). \~$6B U.S. market. Phase 1 already showed:

Phase 2 topline readout expected Q3 2026. That's the binary event. Clean data = stock rips. Miss = it gets destroyed. Classic biotech lottery ticket — except this one has actual fundamentals backing it.

WHY THIS ISN'T JUST ANOTHER BIOTECH GAMBLE:

You know how most clinical-stage biotechs dilute you into oblivion while you hold the bag? Not here. This is genuinely rare.

Revenue nearly doubled YoY ($4.2M → $8.3M Q1). Still losing money obviously, but R&D spend is up because they're actually building a pipeline, not just one drug.

PIPELINE BEYOND THE BINARY:

This isn't a one-trick pony. If 635 hits, the rest of the pipeline gets re-rated too.

THE RISK (yes I'm including this, I've grown):

Phase 2 miss takes the stock down hard. This is a binary event. If you can't stomach a 40-50% drawdown, size accordingly. Don't put in money you need for rent. Actually don't listen to me at all I'm just some guy.

TLDR: ABCL has $655M cash, 4-5 year runway, no dilution risk, and a Phase 2 hot flash drug readout in Q3 that could re-rate the entire company. Management called it their most important catalyst ever. Stock is pricing in fear. I'm pricing in tendies.

Positions or ban:

https://preview.redd.it/jbnjjlx0ul4h1.png?width=1916&format=png&auto=webp&s=a80b2921dfab062845ac1781fafbb463f3678534

This is not financial advice. I eat crayons for breakfast.